Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Open accessThe DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. Whether pembrolizumab plus axitinib would result in better outcomes than sunitinib in such patients was unclear. METHODS: In an open-label, phase 3 trial, we randomly assigned 861 patients with previously untreated advanced clear-cell renal-cell carcinoma to receive pembrolizumab (200 mg) intravenously once every 3 weeks plus axitinib (5 mg) orally twice daily (432 patients) or sunitinib (50 mg) orally once daily for the first 4 weeks of each 6-week cycle (429 patients). The primary end points were overall survival and progression-free survival in the intention-to-treat population. The key secondary end point was the objective response rate. All reported results are from the protocol-specified first interim analysis. RESULTS: After a median follow-up of 12.8 months, the estimated percentage of patients who were alive at 12 months was 89.9% in the pembrolizumab-axitinib group and 78.3% in the sunitinib group (hazard ratio for death, 0.53; 95% confidence interval [CI], 0.38 to 0.74; P<0.0001). Median progression-free survival was 15.1 months in the pembrolizumab-axitinib group and 11.1 months in the sunitinib group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.57 to 0.84; P<0.001). The objective response rate was 59.3% (95% CI, 54.5 to 63.9) in the pembrolizumab-axitinib group and 35.7% (95% CI, 31.1 to 40.4) in the sunitinib group (P<0.001). The benefit of pembrolizumab plus axitinib was observed across the International Metastatic Renal Cell Carcinoma Database Consortium risk groups (i.e., favorable, intermediate, and poor risk) and regardless of programmed death ligand 1 expression. Grade 3 or higher adverse events of any cause occurred in 75.8% of patients in the pembrolizumab-axitinib group and in 70.6% in the sunitinib group. CONCLUSIONS: Among patients with previously untreated advanced renal-cell carcinoma, treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progression-free survival, as well as a higher objective response rate, than treatment with sunitinib. (Funded by Merck Sharp & Dohme; KEYNOTE-426 ClinicalTrials.gov number, NCT02853331.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Combinations of VEGF-targeted agents with anti-PD-1 have demonstrated clinical benefi ts in endometrial carcinoma (pembrolizumab plus lenvatinib; refs.69, 70 ), RCC (pembrolizumab plus axitinib; nivolumab plus cabozantinib; avelumab plus axitinib), and hepatocellular carcinoma (atezolizumab plus bevacizumab; refs.[71][72][73][74][75].”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [71]
In the citing paper
“One study suggested that ICI-colitis correlated with particular strains of microbial flora colonization,19”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Self-citationEscudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., Chevreau, C., Filipek, M., Melichar, B., Bajetta, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61904-7 · Cited by 2,217
Self-citationMotzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., Negrier, S., Szczylik, C., Pili, R., Bjarnason, G. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1293 · Cited by 2,181
Self-citationHeng, D. Y. C., Xie, W., Regan, M. M., Warren, M. A., Golshayan, A. R., Sahi, C., Eigl, B. J., Ruether, J. D., Cheng, T., North, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4809 · Cited by 2,133 · cited 1×
“IMDC risk score is determined by the total number of the following six risk factors that are present: Karnofsky performance-status score of less than 80 (on a scale from 0 to 100, with lower scores indicating greater disability(12)), a time from initial diagnosis to randomization of less than 1 year, a hemoglobin leve…”
MethodSelf-citationKarnofsky performance status revisited: reliability, validity, and guidelines.
Schag, C. C., Heinrich, R. L., & Ganz, P. A. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.3.187 · Cited by 1,517 · cited 1×
“Karnofsky performance-status scores range from 0 to 100, with lower scores indicating greater disability.(12) The programmed death ligand 1 (PD-L1) combined positive score was calculated as the number of PD-L1–positive cells (tumor cells, lymphocytes, and macrophages) divided by the total number of tumor cells, multip…”
MethodSystemic Therapy for Metastatic Renal-Cell Carcinoma
Choueiri, T. K., & Motzer, R. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1601333 · Cited by 1,284
Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Archer, L., Atkins, J. N., Picus, J., Czaykowski, P., Dutcher, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5561 · Cited by 787
Self-citationEscudier, B., Szczylik, C., Hutson, T. E., Demkow, T., Staehler, M., Rolland, F., Negrier, S., Laferriere, N., Scheuring, U. J., Cella, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.3342 · Cited by 490
Self-citationSternberg, C. N., Hawkins, R. E., Wagstaff, J., Salman, P., Mardiak, J., Barrios, C. H., Zarba, J. J., Gladkov, O. A., Lee, E., Szczylik, C., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.010 · Cited by 442
Self-citation
Research works printed but not linked: 1
- Noone AM, Howlader N, Krapcho M, et al., eds. SEER cancer statistics review (CSR), 1975-2015. Bethesda, MD: National Cancer Institute, 2018 (https://seer .cancer .gov/ csr/ 1975_2015/ ).
Cited by
Items 301–400 of 1,002
Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors
Alaiwi, S. A., Nassar, A. H., Xie, W., Bakouny, Z., Berchuck, J. E., Braun, D. A., Baca, S. C., Nuzzo, P. V., Flippot, R., Mouhieddine, T. H., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0866 · Cited by 87
Therapeutic strategies to remodel immunologically cold tumors
Wang, M., Wang, S., Desai, J., Trapani, J. A., & Neeson, P. J. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1226 · Cited by 88
“The combination of pembrolizumab and axitinib for advanced renal cell carcinoma was assessed in a phase III study.(116) The pembrolizumab–axitinib group resulted in prolonged overall- and progression-free survival, as well as a 59.”
BackgroundRini, B. I., Moslehi, J. J., Bonaca, M., Schmidinger, M., Albiges, L., Choueiri, T. K., Motzer, R. J., Atkins, M. B., Haanen, J., Mariani, M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01806 · Cited by 77
Self-citationClinically approved combination immunotherapy: Current status, limitations, and future perspective
Lu, L., Zhan, M., Li, X.-Y., Zhang, H., Dauphars, D. J., Jiang, J., Yin, H., Li, S., Luo, S., Li, Y., et al. (2022) · Current Research in Immunology · doi:10.1016/j.crimmu.2022.05.003 · Cited by 86
Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma
Meng, L., Collier, K. A., Wang, P., Li, Z., Monk, P., Mortazavi, A., Hu, Z., Spakowicz, D. J., Zheng, L., & Yang, Y. (2023) · Cells · doi:10.3390/cells13010034 · Cited by 86
“The KEYNOTE-426 phase III trial evaluated the efficacy of combined pembrolizumab plus axitinib compared to sunitinib monotherapy in patients with previously untreated advanced or metastatic ccRCC [67].”
BackgroundInfluentialMilestones in tumor vascularization and its therapeutic targeting
Palma, M. D., & Hanahan, D. (2024) · Nature Cancer · doi:10.1038/s43018-024-00780-7 · Cited by 88
“The phase 3 KEYNOTE-426 trial demonstrated the superiority of axitinib and pembrolizumab (a PD-1-blocking antibody) over standard-of-care sunitinib in advanced renal cell carcinoma 233 .”
Iacovelli, R., Ciccarese, C., Bria, E., Sergio Bracarda, A., Porta, C., Procopio, G., & Tortora, G. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.06.008 · Cited by 76
PD-L1 induces macrophage polarization toward the M2 phenotype via Erk/Akt/mTOR
Yi, W., Liang, M., Xiong, L., Su, N., Gao, X., & Jiang, Z. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112575 · Cited by 80
Takamatsu, K., Tanaka, N., Hakozaki, K., Takahashi, R., Teranishi, Y., Murakami, T., Kufukihara, R., Niwa, N., Mikami, S., Shinojima, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25865-0 · Cited by 85
Mollica, V., Santoni, M., Matrana, M. R., Basso, U., Giorgi, U. D., Rizzo, A., Maruzzo, M., Marchetti, A., Rosellini, M., Bleve, S., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00861-y · Cited by 82
Rini, B. I., Signoretti, S., Choueiri, T. K., McDermott, D. F., Motzer, R. J., George, S., Powles, T. B., Donskov, F. N., Tykodi, S. S., Pal, S. K., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005445 · Cited by 83
Self-citationDing, X., Zhang, W., You, R., Zou, X., Wang, Z., Ouyang, Y., Peng, L., Liu, Y., Duan, C., Yang, Q., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01450 · Cited by 80
Self-citationGuillebon, É. D., Dardenne, A., Saldmann, A., Séguier, S., Tran, T., Paolini, L., Lebbé, C., & Tartour, É. (2020) · International Journal of Cancer · doi:10.1002/ijc.32889 · Cited by 78
“Initially proposed as a second-line treatment in patients withmetastatic cancers, these drugs are now positioned in the first-line setting alone (melanoma, nonsmall cell lung cancer [NSCLC], head and neck cancer, urothelial tumors, Merkel Cell carcinoma, cutaneous squamous cell carcinoma)(1,2) or in combinationwith ot…”
BackgroundPredictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer
Raimondi, A., Sepe, P., Zattarin, E., Mennitto, A., Stellato, M., Claps, M., Guadalupi, V., Verzoni, E., de Braud, F., & Procopio, G. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01644 · Cited by 78
“Moreover, in the IMmotion151 trial, the combination of the anti-PD-L1 atezolizumab plus bevacizumab prolonged PFS as compared to sunitinib in patients with PD-L1 positive mRCC (15), and the KEYNOTE-426 study demonstrated a significant benefit in terms of OS, PFS and ORR for the anti-PD1 agent pembrolizumab plus axitin…”
ResultEsser, L. K., Branchi, V., Leonardelli, S., Pelusi, N., Simon, A. G., Klümper, N., Ellinger, J., Hauser, S., Gonzalez-Carmona, M. A., Ritter, M., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01775 · Cited by 75
“3% for pembrolizumab plus axitinib (7).”
Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment
Chen, W., Shen, L., Jiang, J., Zhang, L., Zhang, Z., Pan, J., Ni, C., & Chen, Z. (2021) · Biomarker Research · doi:10.1186/s40364-021-00312-w · Cited by 79
“[157] or with alvumab [158] increased progression-free survival.”
BackgroundMasuda, T., Tanaka, N., Takamatsu, K., Hakozaki, K., Takahashi, R., Anno, T., Kufukihara, R., Shojo, K., Mikami, S., Shinojima, T., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003883 · Cited by 80
Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma
Ingels, A., Campi, R., Capitanio, U., Amparore, D., Bertolo, R. G., Carbonara, U., Erdem, S., Kara, Ö., Klatte, T., KRIEGMAIR, M. C., et al. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00592-3 · Cited by 82
Stewart, G. D., Welsh, S. J., Ursprung, S., Gallagher, F. A., Jones, J. O., Shields, J., Smith, C. G., Mitchell, T. J., Warren, A. Y., Bex, A., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01883-7 · Cited by 81
Self-citationHeart Failure With Targeted Cancer Therapies: Mechanisms and Cardioprotection
Hahn, V. S., Zhang, K. W., Sun, L., Narayan, V., Lenihan, D. J., & Ky, B. (2021) · Circulation Research · doi:10.1161/circresaha.121.318223 · Cited by 76
Stereotactic Ablative Radiation for Systemic Therapy–naïve Oligometastatic Kidney Cancer
Hannan, R., Christensen, M., Christie, A. L., Garant, A., Pedrosa, I., Robles, L., Mannala, S., Wang, C., Hammers, H. J., Arafat, W., et al. (2022) · European Urology Oncology · doi:10.1016/j.euo.2022.06.008 · Cited by 77
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics
Tateo, V., Marchese, P. V., Mollica, V., Massari, F., Kurzrock, R., & Adashek, J. J. (2023) · Pharmaceuticals · doi:10.3390/ph16040614 · Cited by 78
Immunotherapy in Older Adults With Cancer
Presley, C. J., Gomes, F., Burd, C. E., Kanesvaran, R., & Wong, M. L. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00138 · Cited by 76
Bu, M. T., Chandrasekhar, P., Ding, L., & Hugo, W. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108211 · Cited by 84
“…or VEGFR2-targeting TKIs have been FDA-approved to treat the highly vascularized RCC (Choueiri et al., 2020, 2021; Motzer et al., 2019, 2021, 2022; Powles et al., 2020; Rini et al., 2019; Rini, Powles, et al., 2019) and hepatocellular carcinoma (HCC) (Cheng et al., 2022; Finn et al., 2020).”
BackgroundMcGregor, B. A., Lalani, A. A., Xie, W., Steinharter, J. A., Bakouny, Z., Martini, D. J., Fleischer, J. H., Alaiwi, S. A., Nassar, A. H., Nuzzo, P. V., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.05.009 · Cited by 71
Ballesteros, P. Á., Chamorro, J., Román, M. S., Pozas, J., Santos, V. G. D., Granados, Á. R., Grande, E., Alonso‐Gordoa, T., & Molina‐Cerrillo, J. (2021) · Cancers · doi:10.3390/cancers13235981 · Cited by 83
Hamada, N., Maeda, A., Takase‐Minegishi, K., Kirino, Y., Sugiyama, Y., Namkoong, H., Horita, N., Yoshimi, R., Nakajima, H., & YCU irAE Working Group (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.803410 · Cited by 80
“Respiratory muscle paralysis, n (%) 34/82 (41) 21/32 (66) 13/50 (26) 0.”
BackgroundSoluble PD-L1 as an early marker of progressive disease on nivolumab
Mahoney, K. M., Ross‐Macdonald, P., Yuan, L., Song, L., Veras, E., Wind‐Rotolo, M., McDermott, D. F., Hodi, F. S., Choueiri, T. K., & Freeman, G. J. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003527 · Cited by 76
Rini, B. I., Plimack, E. R., Stus, V. P., Gafanov, R. A., Waddell, T., Nosov, D., Pouliot, F., Alekseev, B. Y., Soulières, D., Melichar, B., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03867-5 · Cited by 96
“1 by BICR were met at the first interim analysis 2 .”
Self-citationCurrent Approaches to the Treatment of Advanced or Metastatic Renal Cell Carcinoma
Tenold, M. E., Ravi, P. K., Kumar, M., Bowman, I. A., Hammers, H. J., Choueiri, T. K., & Lara, P. N. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_279881 · Cited by 77
Shu, Y., Ding, Y., Dai, B., & Zhang, Q. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2016696 · Cited by 73
“%) than in females (21.04%), which were consistent with epidemiology studies of RCC that age and gender were strongly related to its development [17].”
BackgroundInfluentialBifidobacterium modulation of tumor immunotherapy and its mechanism
Pei, B., Peng, S., Huang, C., & Zhou, F. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03665-x · Cited by 73
Old Player-New Tricks: Non Angiogenic Effects of the VEGF/VEGFR Pathway in Cancer
Ntellas, P., Mavroeidis, L., Gκoura, S., Gazouli, I., Amylidi, A.-L., Papadaki, A., Zarkavelis, G., Mauri, D., Karpathiou, G., Kolettas, E., et al. (2020) · Cancers · doi:10.3390/cancers12113145 · Cited by 76
“Likewise, two other phase III clinical trials have investigated the combination of an immune-checkpoint inhibitor with axitinib, in untreated patients with mRCC [207,208].”
BackgroundEfficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214
Escudier, B. J., Motzer, R. J., Tannir, N. M., Porta, C., Tomita, Y., Maurer, M., McHenry, M. B., & Rini, B. I. (2019) · European Urology · doi:10.1016/j.eururo.2019.10.025 · Cited by 72
“Similarly, in KEYNOTE-426, IMDC risk appeared to be associated with objective response with pembrolizumab plus axitinib, as differences in PFS and OS between this combination and sunitinib decreased in patients with better prognoses according to IMDC risk [6].”
Self-citationThe Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age
Huang, J. J., & Hsieh, J. J.-D. (2020) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2019.12.004 · Cited by 71
Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma
Escudier, B. J. (2019) · New England Journal of Medicine · doi:10.1056/nejme1900887 · Cited by 71
The unique immune microenvironment of liver metastases: Challenges and opportunities
Ciner, A., Jones, K. I., Muschel, R. J., & Brodt, P. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.003 · Cited by 79
Nagaoka, K., Shirai, M., Taniguchi, K., Hosoi, A., Sun, C., Kobayashi, Y., Maejima, K., Fujita, M., Nakagawa, H., Nomura, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001358 · Cited by 75
Mori, K., Abufaraj, M. M., Mostafaei, H., Quhal, F., Fajković, H., Remzi, M., Karakiewicz, P. I., Egawa, S., Schmidinger, M., Shariat, S. F., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.10.006 · Cited by 75
Simonaggio, A., Epaillard, N., Pobel, C., Moreira, M., Oudard, S. M., & Vano, Y. A. (2021) · Cancers · doi:10.3390/cancers13020231 · Cited by 78
“Although ICI combinations have changed the prognostic of mccRCC with impressive overall response rates (ORR) (respectively, 55% with pembrolizumab-axitinib [10] and 42% with nivolumab-ipilimumab [11]), many patients do not respond to immunotherapy, reflecting a primary resistance to ICI.”
BackgroundResultChen, X., Meng, F., & Jiang, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.746976 · Cited by 76
Overcoming Cancer Resistance: Strategies and Modalities for Effective Treatment
Koirala, M., & DiPaola, M. (2024) · Biomedicines · doi:10.3390/biomedicines12081801 · Cited by 75
“This tailored approach ensures the selection of therapies that are likely to be effective for individual patients, thereby enhancing treatment success rates [117,139,140].”
BackgroundThe Changing Therapeutic Landscape of Metastatic Renal Cancer
Angulo, J. C., & Shapiro, O. (2019) · Cancers · doi:10.3390/cancers11091227 · Cited by 75
Fujiwara, Y., Mittra, A., Naqash, A. R., & Takebe, N. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.11 · Cited by 87
“Increases antigen-specific T cell migration [177-181,183-185]”
BackgroundThe Tumor Microenvironment of Bladder Cancer
Hatogai, K., & Sweis, R. F. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-59038-3_17 · Cited by 81
Moran, M., Nickens, D. J., Adcock, K., Bennetts, M., Desscan, A., Charnley, N., & Fife, K. M. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00653-5 · Cited by 78
Carneiro, A., Wroclawski, M. L., Nahar, B., Soares, A., Cardoso, A. P. G., Kim, N. J., & de Carvalho, F. R. T. (2020) · International braz j urol · doi:10.1590/s1677-5538.ibju.2020.04.03 · Cited by 70
“Regarding the choice of first line treatment, we favor, if available, the combination of a tyrosine kinase inhibitors (TKI) with immunotherapy, such as Axitinib with pembrolizumab (31, 32).”
BackgroundGuo, Y., Zhang, W., Ying, J., Zhang, Y., Pan, Y., Qiu, W., Fan, Q., Xu, Q., Ma, Y., Wang, G., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.12.004 · Cited by 68
Zhao, B., Wu, B. C., Feng, N., Zhang, X., Zhang, X., Wei, Y., & Zhang, W. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01426-4 · Cited by 80
Li, M. S. C., Mok, K. K. S., & Mok, T. S. K. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-4444 · Cited by 76
Roelants, C., Pillet, C., Franquet, Q., Sarrazin, C., Peilleron, N., Giacosa, S., Guyon, L., Fontanell, A., Fiard, G., Long, J., et al. (2020) · Cancers · doi:10.3390/cancers12010232 · Cited by 71
Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance
Olino, K. L., Park, T. S., & Ahuja, N. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.001 · Cited by 68
Oza, B., Frangou, E., Smith, B., Bryant, H., Kaplan, R. S., Choodari‐Oskooei, B., Powles, T., Stewart, G. D., Albiges, L. K., Bex, A., et al. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106482 · Cited by 71
Self-citationParikh, R. B., Min, E. J., Wileyto, E. P., Riaz, F., Gross, C. P., Cohen, R. B., Hubbard, R. A., Long, Q., & Mamtani, R. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.4971 · Cited by 66
Wang, C., Lin, J., Wang, Y., Hsi, D. H., Chen, J., Liu, T., Zhou, Y., Ren, Z., Zeng, Z., Cheng, L., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.770631 · Cited by 65
“It has been demonstrated that ICI in conjunction with TKI enhanced efficacy in multiple tumor types (Ascierto et al., 2019; Rini et al., 2019).”
BackgroundMsaouel, P., Goswami, S., Thall, P. F., Wang, X., Yuan, Y., Jonasch, E. W., Gao, J., Campbell, M. T., Shah, A. Y., Corn, P. G., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm6420 · Cited by 68
Argentiero, A., Solimando, A. G., Krebs, M., Leone, P., Susca, N., Brunetti, O., Racanelli, V., Vacca, A., & Silvestris, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051594 · Cited by 64
“The recently published data regarding the combination of anti-angiogenic and anti-PD1 treatment (axitinib in combination with pembrolizumab [59] or avelumab [60]) compared to sunitinib demonstrated a benefit from the combination across the population, regardless of risk class and PD-L1 expression.”
BackgroundDizman, N., Lyou, Y., Salgia, N., Bergerot, P. G., Hsu, J., Enriquez, D., Izatt, T., Trent, J. M., Byron, S. A., & Pal, S. K. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000953 · Cited by 68
Lu, C. C., Li, X. N., Broglio, K. R., Bycott, P. W., Jiang, Q., Li, X., McGlothlin, A. E., Tian, H., & Ye, J. (2021) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-021-00315-7 · Cited by 73
Campbell, M. T., Matin, S. F., Tam, A. L., Sheth, R. A., Ahrar, K., Tidwell, R. S. S., Rao, P., Karam, J. A., Wood, C. G., Tannir, N. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26415-4 · Cited by 66
Navani, V., & Heng, D. Y. C. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.4337 · Cited by 71
Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
Wong, S. K., Nebhan, C. A., & Johnson, D. B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.786046 · Cited by 76
“(34) Pembrolizumab + axitinib vs sunitinib Total – 861 PFS OS”
BackgroundProcopio, G., Sepe, P., Claps, M., Buti, S., Colecchia, M., Giannatempo, P., Guadalupi, V., Mariani, L., Lalli, L., Fucà, G., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.0238 · Cited by 70
Shah, N. J., Sura, S. D., Shinde, R., Shi, J., Singhal, P. K., Robert, N. J., Vogelzang, N. J., Perini, R. F., & Motzer, R. J. (2023) · European Urology Open Science · doi:10.1016/j.euros.2022.12.015 · Cited by 64
Self-citationUveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope?
Castet, F., García‐Mulero, S., Pamplona, R. S., Cuellar, A., Casanovas, O., Mitjana, J. M. C., & Piulats, J. M. (2019) · Cancers · doi:10.3390/cancers11060834 · Cited by 70
“Pembrolizumab and axitinib increased overall survival compared to standard first-line sunitinib [195], and the combination of avelumab–axitinib increased progression-free survival [194].”
BackgroundZoumpourlis, P., Genovese, G., Tannir, N. M., & Msaouel, P. (2020) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2020.11.005 · Cited by 66
Miao, Y. R., Thakkar, K. N., Qian, J., Kariolis, M. S., Huang, W., Nandagopal, S., Yang, T. T. C., Diep, A. N., Cherf, G. M., Xu, Y., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0482 · Cited by 69
“Ongoing efforts to improve the response rate of ICB inhibitors are being pursued in the clinic by combining these inhibitors with cytotoxic drugs, targeted therapies and radiation treatment (10-12).”
BackgroundD’Aniello, C., Berretta, M., Cavaliere, C., Rossetti, S., Facchini, B. A., Iovane, G., Mollo, G., Capasso, M., Pepa, C. D., Pesce, L., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01400 · Cited by 68
Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma
Bhindi, B., Graham, J., Wells, J. C., Bakouny, Z., Donskov, F. N., Fraccon, A. P., Pasini, F., Lee, J., Basappa, N. S., Hansen, A. R., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.04.038 · Cited by 63
Self-citationm 6 A modification patterns and tumor immune landscape in clear cell renal carcinoma
Zhong, J., Liu, Z., Cai, C., Duan, X., Deng, T., & Zeng, G. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001646 · Cited by 83
Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis
Zhu, J., Yan, L., & Wang, Q. (2021) · Journal of Ovarian Research · doi:10.1186/s13048-021-00862-5 · Cited by 72
Farooq, M. Z., Aqeel, S. B., Lingamaneni, P., Pichardo, R., Jawed, A., Khalid, S., Banskota, S. U., Fu, P., & Mangla, A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.7722 · Cited by 69
Motzer, R., Porta, C., Alekseev, B. Y., Rha, S. Y., Choueiri, T. K., Mendez-Vidal, M. J., Hong, S.-H., Kapoor, A., Goh, J. C. H., Eto, M., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00212-1 · Cited by 63
Self-citationCarril-Ajuria, L., Desnoyer, A., Meylan, M., Dalban, C., Naigeon, M., Cassard, L., Vano, Y. A., Rioux-Leclercq, N. C., Chouaïb, S., Beuselinck, B., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004885 · Cited by 69
Paderi, A., Giorgione, R., Giommoni, E., Mela, M., Rossi, V., Doni, L., Minervini, A., Carini, M., Pillozzi, S., & Antonuzzo, L. (2021) · Cancers · doi:10.3390/cancers13040860 · Cited by 62
Kelley, R. K., Oliver, J. W., Hazra, S., Benzaghou, F., Yau, T. C. C., Cheng, A., & Rimassa, L. (2020) · Future Oncology · doi:10.2217/fon-2020-0283 · Cited by 65
Kim, J., Hong, J., Lee, J., Lahiji, S. F., & Kim, Y. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.02.002 · Cited by 65
Xu, X., Mu, L., Li, L., Liang, J., Zhang, S., Jia, L., Yang, X., Dai, Y., Zhang, J., Wang, Y., et al. (2022) · Science Advances · doi:10.1126/sciadv.abi8683 · Cited by 66
Nowak-Sliwinska, P. M., van Beijnum, J. R., Griffioen, C. J., Huinen, Z. R., Sopesens, N. G., Schulz, R., Jenkins, S. V., Dings, R. P. M., Groenendijk, F. H., Huijbers, E. J. M., et al. (2022) · Angiogenesis · doi:10.1007/s10456-022-09863-4 · Cited by 66
“In this field > 90 clinical trials, mostly involving immune checkpoint inhibitors, are currently ongoing and to date 5 combination therapies have been FDA approved for treatment of RCC [34, 48], non-small cell lung cancer [33] and hepatocellular carcinoma [49].”
BackgroundRegan, M. M., Jegede, O. A., Mantia, C. M., Powles, T. B., Werner, L. L., Motzer, R. J., Tannir, N. M., Lee, C., Tomita, Y., Voss, M. H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2283 · Cited by 67
Self-citationMori, K., Mostafaei, H., Miura, N., Karakiewicz, P. I., Luzzago, S., Schmidinger, M., Bruchbacher, A., Pradère, B., Egawa, S., & Shariat, S. F. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02684-8 · Cited by 63
Donskov, F. N., Xie, W., Overby, A., Wells, J. C., Fraccon, A. P., Sacco, C. S. P., Porta, C., Stukalin, I., Lee, J., Koutsoukos, K., et al. (2020) · European Urology Oncology · doi:10.1016/j.euo.2020.01.001 · Cited by 61
“Motzer et al [14] 2007 Sunitinib Interferon-a Yes (not per arm) MSKCC No AVOREN [15] 2007 Bevacizumab + interferon-a Interferon-a Yes MSKCC MSKCC Global ARCC [16] 2007 Temsirolimus Interferon-a Yes MSKCC No CALGB 90206 [17] 2008 Bevacizumab + interferon-a Interferon-a No MSKCC MSKCC Sternberg et al [18] 2010 Pazopanib…”
BackgroundMangan, B. L., McAlister, R. K., Balko, J. M., Johnson, D. B., Moslehi, J. J., Gibson, A., & Phillips, E. J. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14433 · Cited by 65
“Most recently, ICIs have been approved in combination with oral tyrosine kinase inhibitors for the treatment of renal cell carcinoma and endometrial cancer.(7,8)”
BackgroundHarrison, M. R., Costello, B. A., Bhavsar, N. A., Vaishampayan, U. N., Pal, S. K., Zakharia, Y., Jim, H., Fishman, M., Molina, A. M., Kyriakopoulos, C. E., et al. (2021) · Cancer · doi:10.1002/cncr.33494 · Cited by 66
Emamekhoo, H., Olsen, M. R., Carthon, B. C., Drakaki, A., Percent, I. J., Molina, A. M., Cho, D. C., Bendell, J. C., Gordan, L., Kalebasty, A. R., et al. (2021) · Cancer · doi:10.1002/cncr.34016 · Cited by 63
Liu, C., Wang, M., Xu, C., Li, B., Chen, J., Chen, J., & Wang, Z. (2021) · Journal of Immunology Research · doi:10.1155/2021/8970173 · Cited by 67
“For instance, in the clinical trial of Keynote 426 (24% of patients had bone metastases), the combination of pembrolizumab and tyrosine kinase inhibitor axitinib, compared with sunitinib monotherapy, improved the OS, PFS, and ORR both in the overall population and in subgroups with different risks regardless of the ex…”
BackgroundThe Landscape of Immunotherapy Resistance in NSCLC
Frisone, D., Friedlaender, A., Addeo, A., & Tsantoulis, P. K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.817548 · Cited by 65
Li, C., Tian, Y., Zheng, Y., Yuan, F., Shi, Z., Yang, L., Chen, H., Jiang, L., Wang, X., Zhao, P., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00795 · Cited by 74
Porcari, S., CICCARESE, C., Heidrich, V., Rondinella, D., Quaranta, G., Severino, A., Arduini, D., Buti, S., Fornarini, G., Primi, F., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04189-2 · Cited by 70
Flaifel, A., Xie, W., Braun, D. A., Ficial, M., Bakouny, Z., Nassar, A. H., Jennings, R. B., Escudier, B. J., George, D. J., Motzer, R. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1135 · Cited by 61
Self-citationAmbrosetti, D., Coutts, M., Paoli, C., Durand, M., Borchiellini, D., Montemagno, C., Rastoin, O., Borderie, A., Grépin, R., Rioux-Leclercq, N. C., et al. (2021) · British Journal of Urology · doi:10.1111/bju.15506 · Cited by 64
Self-citationLi, Y., Jia, G.-D., Lv, X., Xie, S., Guo, S.-S., Lin, D.-F., Liu, L., Luo, D., Li, Y., Deng, S.-W., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40402-x · Cited by 65
“…immune checkpoint inhibitors with anti-angiogenesis drugs has previously shown synergistic ef fi cacy in patients with several types of solid tumors 21 – 24, 32, 33, 42 , and our trial aims to assess the Despite of a high proportion of patients with RM-NPC can achieve a response with GPplus…”
Clinical development of immuno-oncology therapeutics
Wang, J., Chen, Q., Shan, Q., Liang, T., Forde, P. M., & Zheng, L. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217616 · Cited by 61
Huemer, F., Leisch, M., Geisberger, R., Melchardt, T., Rinnerthaler, G., Zaborsky, N., & Greil, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082856 · Cited by 62
“Extensively investigated biomarkers such as programmed cell death-ligand 1 (PD-L1) [10–13] help predicting clinical outcome with ICI whereas negativity does not exclude responses [14,15].”
BackgroundPal, K., Madamsetty, V. S., Dutta, S. K., & Mukhopadhyay, D. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s204221 · Cited by 58
“In addition, two separate large Phase III trials demonstrated the superiority of avelumab (a programmed death ligand 1 inhibitor) plus axitinib and pembrolizumab (a programmed death 1 inhibitor) plus axitinib over sunitinib with respect to progression-free survival and the objective response rate.(26,27) Pembrolizumab…”
BackgroundTumors resurrect an embryonic vascular program to escape immunity
Huijbers, E. J. M., Khan, K. A., Kerbel, R. S., & Griffioen, A. W. (2022) · Science Immunology · doi:10.1126/sciimmunol.abm6388 · Cited by 64
Bergmann, L., Albiges, L. K., Ahrens, M., Gross‐Goupil, M., Boleti, E., Gravis, G., Fléchon, A., Grimm, M., Bedke, J., Barthélémy, P., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.03.016 · Cited by 75
Self-citationGrimm, M., Bex, A., Santis, M. D., Ljungberg, B., Catto, J. W. F., Rouprêt, M., Hussain, S. A., Bellmunt, J., Powles, T., Wirth, M., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.05.041 · Cited by 61
Self-citationGrünwald, V., Voss, M. H., Rini, B. I., Powles, T. B., Albiges, L. K., Giles, R. H., & Jonasch, E. W. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0949-9 · Cited by 60
Self-citationImmunotherapy in older patients with cancer
Granier, C., Gey, A., Roncelin, S., Weiss, L., Paillaud, É., & Tartour, É. (2020) · Biomedical Journal · doi:10.1016/j.bj.2020.07.009 · Cited by 63
“[53] Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al.”
Background
Metadata
- Authors
- Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., Vynnychenko, I., Kryzhanivska, A., Bondarenko, I., Azevedo, S. J., Borchiellini, D., Szczylik, C., Markus, M., McDermott, R. S., Bedke, J., Tartas, S., Chang, Y.-H., Tamada, S., Shou, Q., Perini, R. F., Chen, M., Atkins, M. B., & Powles, T.
- Affiliations
- Fox Chase Cancer Center (US)
- From the Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Dnipropetrovsk Medical Academy of Ministry of Health of Ukraine (V.S.) and Dnipropetrovsk Medical Academy (I.B.), Dnipro, Sumy State University, Sumy Regional Oncology Center, Sumy (I.V.), and Ivano-Frankivsk National Medical University, Ivano-Frankivsk (A.K.) — all in Ukraine; the Russian Scientific Center of Roentgen Radiology (R.G.), Central Clinical Hospital with Outpatient...
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Rini, Brian I.
- Plimack, Elizabeth R.
- Stus, Viktor
- Gafanov, Rustem
- Nosov, Dmitry
- Pouliot, Frédéric
- Alekseev, Boris
- Soulières, Denis
- Melichar, Bohuslav
- Vynnychenko, Ihor
- Kryzhanivska, Anna
- Bondarenko, Igor
- Borchiellini, Delphine
- Szczylik, Cezary
- Bedke, Jens
- Tamada, Satoshi
- Perini, Rodolfo F.
- Atkins, Michael B.
- Powles, Thomas
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-03-21
- Volume
- 380
- Issue
- 12
- Pages
- 1116-1127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2913745075
- Cited by
- 3,403
- References
- 23
- Citations by year
- 2026: 269 · 2025: 323 · 2024: 431 · 2023: 440 · 2022: 589 · 2021: 597 · 2020: 532 · 2019: 220
- FWCI
- 357.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Oncourology (Russian Society of Oncourologists) (submittedVersion, cc-by)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Funders
- Merck Sharp and Dohme
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Keywords
- pembrolizumab, axitinib, sunitinib, immune checkpoint inhibitors, PD-1 inhibitors, PD-L1 expression, overall survival, progression-free survival, objective response rate, first-line therapy, adverse events, immune-related adverse events, tyrosine kinase inhibitors, IMDC risk groups
- MeSH terms
- Sunitinib, Axitinib, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Survival Rate, Single-Blind Method, Intention to Treat Analysis, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.